Bleselumab

Drug Profile

Bleselumab

Alternative Names: 4D11; ASKP 1240

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; Kyowa Hakko Kirin
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal transplant rejection
  • Phase I Transplant rejection
  • Discontinued Plaque psoriasis

Most Recent Events

  • 30 Sep 2016 Astellas Pharma plans a phase II trial for Focal segmental glomerulosclerosis in USA (NCT02921789)
  • 10 Aug 2015 Phase-II development is ongoing for Transplant organ rejection (Prevention) in USA
  • 01 Jan 2015 Astellas and Kyowa Hakko Kirin completes a phase II trial in Plaque psoriasis in Australia, Canada and New Zealand (NCT01585233)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top